LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI-Powered Blood Test Enables Detection, Analysis and Profiling of Cancer Tumors

By LabMedica International staff writers
Posted on 10 Dec 2024
Print article
Image: The new method will help guide cancer treatment using blood samples (Photo courtesy of 123RF)
Image: The new method will help guide cancer treatment using blood samples (Photo courtesy of 123RF)

Mutational signatures are changes in DNA patterns caused by cancer’s effects on cells in the body. These signatures can provide valuable insights into the cancer, such as the potential causes behind its development and which therapies may be most effective. Currently, obtaining this information requires whole genome sequencing of a tissue biopsy from the cancer, which is then compared to the patient's matched normal DNA sample. A standard biopsy that involves removing tissue or cells is costly and time-consuming, and it can also be difficult to collect tissue biopsy samples, especially when the tumor is located in hard-to-reach areas.

Researchers at Peter MacCallum Cancer Centre (Victoria, Australia) have now developed a method that utilizes circulating tumor DNA (ctDNA) from a patient's blood to detect cancer-related DNA changes. Their innovative approach, known as MisMatchFinder, uses an algorithm to identify these changes through a simple blood test. This method, published in Nature Communications, offers the potential to make genome sequencing more accessible and efficient, enabling quicker, personalized treatment plans for cancer patients. Moreover, it could revolutionize cancer monitoring by tracking changes in the disease over time, eliminating the need for repeated biopsies.

“Excitingly, this new methodology will allow us to observe what is happening to the tumor over various time points,” said study co-author Dr. Dineika Chandrananda. “MisMatchFinder brings considerable advances to the clinic and holds the potential to provide new insights into the use of mutational signatures. We believe that this knowledge will help guide and inform clinical decisions to optimize research led cancer treatment strategies.”

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.